Analysis of p16^INK4a expression and survival of cervical cancer patients.

<p>Forest plot of RR for OS (A) and DFS (B) among included studies. Combined RR was calculated by a random mode.</p

Literature search strategy and selection of articles.

<p>A total of 346 articles were selected for the meta-analysis by browsing the databases PubMed, Embase and Wanfang, of which 324 were excluded after reviewing the title and abstract, seven articles were excluded after reviewing the full publications, the reasons for exclusion were: (a) Non-association studies (b) researchers in the article did not use neither histopathologic analysis nor close clinical and imaging follow-up for at least 6 months, (c) association studies for other diseases (d), non-original articles, (e) data couldn’t be extracted or (f) repeated data from the same or similar population. Finally, a total of 15 studies with 1633 patients, who fulfilled all of the inclusion criteria, were considered for the analysis.</p

Prognostic Significance of Overexpressed p16^INK4a in Patients with Cervical Cancer: A Meta-Analysis

<div><p>Background</p><p>p16^INK4a is a tumor suppressor protein which is induced in cells upon the interaction of high-risk HPV E7 with the retinoblastoma protein by a positive feedback loop, but cannot exert its suppressing effect. Previous reports suggested that p16^INK4a immunostaining allows precise identification of even small CIN or cervical cancer lesions in biopsies. The prognostic value of overexpressed p16^INK4a in cervical cancer has been evaluated for several years while the results remain controversial. We performed a systematic review and meta-analysis of studies assessing the clinical and prognostic significance of overexpression of p16^INK4a in cervical cancer.</p><p>Methods</p><p>Identification and review of publications assessing clinical or prognostic significance of p16^INK4a overexpression in cervical cancer until March 1, 2014. A meta-analysis was performed to clarify the association between p16^INK4a overexpression and clinical outcomes.</p><p>Results</p><p>A total of 15 publications met the criteria and comprised 1633 cases. Analysis of these data showed that p16^INK4a overexpression was not significantly associated with tumor TNM staging (I+II vs. III+IV) (OR = 0.75, 95% confidence interval [CI]: 0.35–1.63, P = 0.47), the tumor grade (G1+ G2 vs. G3) (OR = 0.78, 95% CI: 0.39–1.57, P = 0.49), the tumor size (<4 vs. ≥4 cm) (OR = 1.10, 95% CI: 0.45–2.69, P = 0.83), or vascular invasion (OR = 1.20, 95% CI: 0.69–2.08, P = 0.52). However, in the identified studies, overexpression of p16^INK4a was highly correlated with no lymph node metastasis (OR = 0.51, 95% CI: 0.28–0.95, P = 0.04), increased overall survival (relative risk [RR]: 0.42, 95% CI: 0.24–0.72, P = 0.002) and increased disease free survival (RR: 0.60, 95% CI: 0.44–0.82, P = 0.001).</p><p>Conclusions</p><p>This meta-analysis shows overexpression of p16^INK4a in cervical cancer is connected with increased overall and disease free survival and thus marks a better prognosis.</p></div

Egger’s test of funnel plot asymmetry.

<p>df: deflection.</p><p>Egger’s test of funnel plot asymmetry.</p

Forest plot depiction of p16^INK4a expression and OR for clinical pathologic features.

<p>Clinicopathological parameters investigated are lymph node status (A), TMN classification (B), tumor grade (C), size of tumor (D), vascular invasion (E). OR with corresponding confidence intervals are shown.</p

Main characteristics and results of the eligible studies.

<p>IHC; immunohistochemistry; ND: not documented.</p><p>Main characteristics and results of the eligible studies.</p

Additional file 1: of Periostin enhances adipose-derived stem cell adhesion, migration, and therapeutic efficiency in Apo E deficient mice with hind limb ischemia

is Figure S1 showing that P3 GFP-ADSCs were strongly double positive for GFP and the stem cell surface antigens CD44 and CD105, and negative for CD11b, CD31, CD34, CD45, CD133, and MHC-II. (TIFF 2302 kb

Video 1: sj-vid-1-phl-10.1177_0268355518790407 -Supplemental material for Endovascular management of extensive lower extremity acute deep vein thrombosis with AngioJet rheolytic thrombectomy plus catheter-directed thrombolysis from contralateral femoral access

<p>Supplemental material, Video 1: sj-vid-1-phl-10.1177_0268355518790407 for Endovascular management of extensive lower extremity acute deep vein thrombosis with AngioJet rheolytic thrombectomy plus catheter-directed thrombolysis from contralateral femoral access by Guang Liu, Zhen Zhao, Chaoyi Cui, Kaichuang Ye, Minyi Yin, Xaiobing Liu, Jinbao Qin, Xintian Huang, Min Lu, Mier Jiang, Weimin Li and Xinwu Lu in Phlebology</p

Video 2: sj-vid-2-phl-10.1177_0268355518790407 -Supplemental material for Endovascular management of extensive lower extremity acute deep vein thrombosis with AngioJet rheolytic thrombectomy plus catheter-directed thrombolysis from contralateral femoral access

<p>Supplemental material, Video 2: sj-vid-2-phl-10.1177_0268355518790407 for Endovascular management of extensive lower extremity acute deep vein thrombosis with AngioJet rheolytic thrombectomy plus catheter-directed thrombolysis from contralateral femoral access by Guang Liu, Zhen Zhao, Chaoyi Cui, Kaichuang Ye, Minyi Yin, Xaiobing Liu, Jinbao Qin, Xintian Huang, Min Lu, Mier Jiang, Weimin Li and Xinwu Lu in Phlebology</p